HoneyNaps Participation at World Sleep Congress
HoneyNaps USA has successfully concluded its participation in the 18th World Sleep Congress held recently. This notable international event gathered experts and professionals in sleep medicine from various countries, creating a unique platform for companies like HoneyNaps to showcase advancements in sleep-related technology.
Showcasing Groundbreaking AI Technology
During the congress, HoneyNaps introduced its FDA-approved AI PSG auto-scoring solution, SOMNUM. The company presented two main versions of this innovative product: the installable SOMNUM Pro and the web-based SOMNUM Cloud. This technology aims to simplify and enhance the process of scoring polysomnography data, providing significant clinical applicability.
SOMNUM Pro and SOMNUM Cloud
SOMNUM Pro is designed as a stand-alone software application that can be installed on hospital systems. It effectively analyzes PSG data using advanced AI algorithms to generate comprehensive polysomnography reports. This software includes a user-friendly scoring window that visually represents how the AI interprets various sleep events.
On the other hand, SOMNUM Cloud offers a cloud-based solution that requires no installation. Users simply upload data files (EDF) from PSG equipment, and the AI auto-scores this data to deliver downloadable reports securely. The system adheres to strict HIPAA regulations and has obtained ISO/IEC 27001 certification, ensuring high-security standards for medical data protection.
Global Interest and Participation
The congress attracted medical professionals from over 35 countries, including notable attendees from advanced markets such as the UK, Germany, and France, as well as emerging markets in Latin America, Asia, and the Middle East. HoneyNaps witnessed tremendous engagement, exceeding visitor turnout comparisons to both previous exhibitions and other international congresses in the field.
Following the event, HoneyNaps received over 260 business inquiries, alongside the signing of six new contracts. The company is currently in discussions to establish exclusive distributor agreements in several markets, actively exploring various supply models and trial applications for its advanced scoring technologies.
The Path to Expansion
President Taekyoung (Sean) Ha emphasized the company's strategy to build on the interest generated at the congress. HoneyNaps plans to follow up with trial participants and work on establishing distributor systems while navigating regulatory approvals for its medical devices across targeted international markets. The company aims to expand its reach rapidly, leveraging not only its technological capabilities but also the potential for strong collaboration in the healthcare sector.
Conclusion and Future Directions
HoneyNaps recognizes the vital role of international collaboration in achieving its goals. The company plans to establish official networks in regions demonstrating strong market responses and considers undertaking joint research projects with reputable medical institutions. As HoneyNaps continues to innovate and respond to global demands, it remains dedicated to enhancing patient care through its state-of-the-art sleep technology solutions.
Frequently Asked Questions
1. What technologies did HoneyNaps showcase at the World Sleep 2025?
HoneyNaps showcased its FDA-approved AI-based PSG auto-scoring solutions, SOMNUM Pro and SOMNUM Cloud.
2. How does SOMNUM Pro differ from SOMNUM Cloud?
SOMNUM Pro is a standalone software for hospitals, while SOMNUM Cloud is a web-based service that requires no installation.
3. What was the response from attendees at the congress?
The company received over 260 inquiries and signed six contracts, indicating a strong interest in their solutions.
4. How does HoneyNaps ensure data protection?
SOMNUM Cloud complies with HIPAA regulations and is certified with ISO/IEC 27001 to ensure high data security standards.
5. What are HoneyNaps' future plans for expansion?
The company plans to develop distributor networks, pursue regulatory approvals, and engage in joint research projects to enhance its global presence.
